Virax Biolabs Group Ltd VRAX
Annual
Quarterly
FY2025 · ended Mar 31, 2025 · Revenue $6,331, -96.0% YoY · Filed Jul 2, 2025
Virax Biolabs Group Ltd (VRAX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Mar 31, 2025, it reported revenue of $6,331 and a net loss of $6.1 million. Free cash flow was -$5.2 million. As of Mar 31, 2025 it held $4.2 million in cash and investments and $344,536 in total debt.
Revenue
$6,331
-96.0% vs prior year
Net income
$-6.07M
+10.0% vs prior year
Operating cash flow
$-4.56M
+26.9% vs prior year
Free cash flow
$-5.17M
+28.2% vs prior year
EPS
$-1.62
+51.8% vs prior year
Dividend per share
None
Shares outstanding
579,218
-86.7% vs prior year
Net cash
$3.88M
FY 2025
Operating margin
-97344.8%
FY 2025
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|
| Revenue | $6,331 | $156,419 | $8,561 | $0 |
| Operating income | -$6.2M | -$6.5M | -$5.7M | -$1.7M |
| Net income | -$6.1M | -$6.7M | -$5.5M | -$1.7M |
| Diluted EPS | -$1.62 | -$3.36 | -$5.13 | — |
| Operating cash flow | -$4.6M | -$6.2M | -$4.2M | -$809,070 |
| Free cash flow | -$5.2M | -$7.2M | — | — |
| Total assets | $6.4M | $5.5M | $9.8M | $48,706 |
| Total liabilities | $964,750 | $345,194 | $908,401 | $1.2M |
| Stockholders' equity | $5.5M | $5.1M | $8.9M | -$1.2M |
| Cash and investments | $4.2M | $3.6M | $9.4M | $21,756 |
| Total debt | $344,536 | $224,300 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 9, 2026 | Oct 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Aug 26, 2026 | Aug 21, 2026 |
| 6-K | Current report (foreign issuer) | Aug 18, 2026 | Aug 18, 2026 |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
All 159 Virax Biolabs Group Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.